CLL homepage

J&J withMe in your country

Chronic lymphocytic leukaemia (CLL) and you

Welcome to the CLL area of the J&J withMe platform, a section dedicated to supporting people living with the disease.

Receiving a diagnosis of CLL can come with a raft of different emotions, but by building up your knowledge about the disease, you can prepare yourself for what is to come. It’s the first step towards effectively managing your CLL.

Each person will experience the disease differently. Some will require urgent care, while others will experience requiring treatment much later, if at all, due to its slow development. Understanding CLL and the various treatment options that are available can help you make much more informed decisions during consultations, enabling you to help tailor your treatment to your personal needs, and overall, better prepare you to manage a life with CLL. Remember, your doctor should be the first person you talk to about more specific and in-depth queries.

Key topics

About CLL

Gain an overview of chronic lymphocytic leukaemia (CLL), what it is, getting diagnosed and the stages.

Symptoms

Information about the main signs of CLL and what to expect with disease progression.

Treatments

Learn more about the different treatments available to you.

Living with CLL

Discover practical tips for helping you manage and live with CLL and its symptoms.

Your healthcare team

Find out about the key people in your healthcare team, what to expect in consultations and key questions to ask.

Support and caregivers

Find links to local support networks, online forums, and additional information to help caregivers to provide the best support they can.

BTKi Treatment Patient Guide

Discover a helpful guide designed to support you in living well during your Bruton’s tyrosine kinase inhibitor (BTKi) treatment journey.

References

Global Patient and Carer Experience Survey. (2021). Available at: https://www.clladvocates.net/wp-content/uploads/2023/09/Global-Leukemia-Experience-Survey_Full-Report.pdf. Last accessed: November 2024.
Alu, Aqu et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022 Oct;15:138.
Tam CS, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Curr Med Res Opin. 2023 Sep:1-7.
Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762-768.
DrugBank Online. Warfarin. Available at: https://go.drugbank.com/drugs/DB00682. Last accessed: November 2024.
Lipsky A, et al. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec;2020(1):336-345.
Cancer Research UK. Ibrutinib (Imbruvica). Available at: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ibrutinib. Last accessed: November 2024.
Macmillan Cancer Support. Ibrutinib (Imbruvica). Available at: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/ibrutinib. Last accessed: November 2024.
Quartermaine C, et al. (2023). Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 5(5), pp.570–590.
Zeynep Tuğba Güven. CLL-256 Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report. 2024;24;Sup 1: S349-S350.
Valla K, et al. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors. Cancer Network Oncology. 2018 Nov; 32(11):574-575.
Logo Janssen | Pharmaceutical Companies of Johnson & Johnson